Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 4/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21027857 | 0.94 | PTGDR2 (0.47) | PTGDR2HTR6PTGDRL3MBTL1TDP1 | |
| SCHEMBL21027976 | 0.94 | PTGDR2 (0.49) | PTGDR2PTGDR | |
| SCHEMBL21028014 | 0.86 | PTGDR2 (0.42) | PTGDR2MEN1RAB9AKMT2AHTR6 | |
| SCHEMBL21028015 | 0.81 | ALDH1A1 (0.38) | PTGDR2MEN1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL21028025 | 0.77 | PTGDR2 (0.46) | PTGDR2PTGDR | |
| SCHEMBL21027975 | 0.75 | PTGDR2 (0.44) | PTGDR2MEN1KMT2AHTR6PTGDR | |
| SCHEMBL21028003 | 0.75 | PTGDR2 (0.49) | PTGDR2PTGDR | |
| SCHEMBL21028324 | 0.74 | PTGDR2 (0.42) | PTGDR2PTGDR | |
| SCHEMBL21028287 | 0.73 | PTGDR2 (0.41) | PTGDR2PTGDR | |
| SCHEMBL21028077 | 0.67 | MEN1 (0.41) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-13 | — | — | US | disclosed |
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-30 | — | — | US | disclosed |
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403466-A1 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR | NR3C2, CRHR2, CRHR1 | PTGDR2 152/4885MEN1 1870/4885RAB9A 3506/4885 |
| US-11524958-B2 | Tricyclic compound as CRTH2 inhibitor | NR1H2, NR3C2, NR1H4 | PTGDR2 313/4885MEN1 2955/4885RAB9A 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.